Center to speed up antibacterial drugs for hard-to-treat infections
Official title: Center for accelerated development of drug candidates targeting high threat bacterial infections
Funded at Hackensack University Medical Center · NIH-11372866 · Data updated 2026-11-12
A national center at Hackensack University Medical Center aims to speed up the development of new antibiotics to fight high-threat, drug-resistant bacterial infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project start | June 20, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $295,745 |
| NIH project number | 5U19AI189168-02 |
| Project ID | NIH-11372866 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with high-risk, drug-resistant bacterial infections who have limited or no effective treatment options.
✕Less likely to help
Patients with infections caused by well-controlled or non-resistant bacteria may not directly benefit from this program.
What this research studies
This grant funds a translational drug accelerator focused on advancing antibacterial small molecule programs toward preclinical development and IND submissions. It emphasizes streamlined operations, secure data sharing, IP protection, and effective grant and fiscal management to keep drug projects moving efficiently. Researchers from academic and industry backgrounds will collaborate to optimize compounds against multidrug-resistant bacteria and coordinate projects under an integrated Administrative Core.
Why it matters
Potential benefit: If successful, patients could gain access to faster-available new antibiotics for resistant infections.
How similar studies have gone: Previous antibiotic development efforts have shown that streamlined translational centers can accelerate candidate selection and IND-enabling work.
Where this research is happening
-
Hackensack University Medical Center
Hackensack, United States Active
Researchers
- Principal investigator: Perlin, David S — Hackensack University Medical Center
- Study coordinator: Perlin, David S
Related research
Other NIH-funded projects on the same topics.
-
Host-Directed Orynotide for MDR Gram-Negative Infections
A new drug candidate called Orynotide MTD12813 is being developed to treat serious drug-resistant infections caused by bacteria like Acinetobacter and Enterobacteriaceae.
-
Genomic-informed, low-cost, portable test to rapidly identify drug-resistant bacterial infections
A portable, affordable test called BADLOCK could quickly identify bacteria and resistance genes from blood samples to help treat drug-resistant infections.
-
Novel BMX antibiotics for tough Gram-negative infections
A new class of BMX antibiotics is being developed to fight hard-to-treat Gram-negative infections like Acinetobacter baumannii in patients.
-
Center accelerating antibiotic development for high-threat bacterial infections
A research center in academia–industry collaboration is speeding up the development of new antibiotics to fight highly resistant bacteria so patients have better treatment options.
-
PACC1 in the body’s defense against bacterial infections and sepsis
A study exploring how a protein called PACC1 helps immune cells fight bacteria and prevent sepsis, with potential benefits for people at risk of severe infections.
-
Comparative safety of antibiotics for common infections in pregnancy
This project looks at which antibiotics are safest for babies when used to treat common infections in pregnant women.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.